Himawan Fernando, Ziad Nehme, Catherine Milne, Jessica O'Brien, Stephen Bernard, Michael Stephenson, Paul S Myles, Jeffrey Lefkovits, Karlheinz Peter, Angela Brennan, Diem Dinh, Emily Andrew, Andrew J Taylor, Karen Smith, Dion Stub
BACKGROUND: Opioid analgesia has been shown to interfere with the bioavailability of oral P2Y12 inhibitors prompting the search for safe and effective non-opioid analgesics to treat ischemic chest pain. METHODS: The AVOID-2 trial was a prospective, phase II, prehospital, open-label, non-inferiority, randomized controlled trial enrolling patients with suspected STEACS with moderate to severe pain (numerical rating scale (NRS) at least 5/10). Intravenous lidocaine (maximum dose 300 mg) or intravenous fentanyl (up to 50 µg every 5 min) were administered as prehospital analgesia...
December 10, 2022: European Heart Journal. Acute Cardiovascular Care